A clinical trial using the anti-depressant nomifensine in Parkinsonism is reported. Eighteen subjects not receiving levodopa participated. The drug had a small, but significant anti-Parkinsonian effect. No troublesome side effects were encountered. In the treatment of Parkinsonism, nomifensine may be considered as an alternative to amantadine or anticholinergics, especially where depression is an added feature.
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Online ISSN 1468-330X
Copyright © 2009 by the BMJ Publishing Group Ltd. All rights reserved.
